NNovo Nordisk Read More Novo Nordisk signs $1.3 billion deal for long-acting obesity shots2026-09-25 Novo Nordisk signed a global licensing agreement with Swedish drug-delivery company Nanexa worth up to €1.165 billion ($1.3…
NNovo Nordisk Read More Nanexa and Novo enter into EUR 1.165 billion global license and collaboration agreement for long-acting injectables2026-09-25 The agreement grants Novo a global exclusive license to Nanexa’s proprietary PharmaShell® atomic layer deposition (ALD) drug delivery…